Stahl B U, Beer D G, Weber L W, Rozman K
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417.
Toxicology. 1993 Mar 30;79(1):81-95. doi: 10.1016/0300-483x(93)90207-9.
We have previously shown that the rate of hepatic gluconeogenesis is reduced in TCDD-treated rats and that this decrease in carbohydrate production is associated with a dose-dependent reduction of the activity of PEPCK, the rate limiting enzyme of gluconeogenesis. This derailment of glucose metabolism has been suggested to be the critical lesion in acute TCDD toxicity. To further elucidate the mechanism of decreased PEPCK activity we performed Northern blot analyses using a cDNA probe complementary to a portion of the mRNA coding for PEPCK. We have demonstrated that 4 and 8 days after TCDD treatment (125 micrograms/kg, p.o.) liver PEPCK mRNA in Sprague-Dawley rats was decreased to very low levels as compared to vehicle-treated and pair-fed control animals. This decline of PEPCK mRNA was paralleled by decreased levels of PEPCK protein, as revealed by Western blot analyses and was accompanied by a reduction in the enzymatic activity of PEPCK. These results indicate that the decrease of PEPCK activity by TCDD is most likely the result of decreased expression of the PEPCK gene. These together with previous results also suggest that many of the physiological responses occurring in TCDD-treated animals (reduced feed intake, decreased insulin, increased corticosterone, increased glucagon and cAMP levels) which would normally stimulate PEPCK gene expression, are ineffective. Furthermore tryptophan 2,3-dioxygenase (TdO) activity, which is regulated in a very similar fashion to PEPCK activity, is also reduced after TCDD treatment, suggesting a common mechanism by which TCDD alters the regulation of these enzymes. P-450 1A1 mRNA and related EROD activity were maximally induced under the conditions of these experiments and represent a positive control for TCDD-related alterations of gene expression. However, because of differences in the dose-response characteristics of TCDD-induced reduction of PEPCK activity and induction of EROD activity an involvement of the Ah receptor in the reduction of PEPCK activity cannot be postulated.
我们之前已经表明,在经TCDD处理的大鼠中,肝脏糖异生速率降低,且这种碳水化合物生成的减少与糖异生的限速酶PEPCK活性的剂量依赖性降低有关。葡萄糖代谢的这种紊乱被认为是急性TCDD毒性中的关键损伤。为了进一步阐明PEPCK活性降低的机制,我们使用与编码PEPCK的mRNA的一部分互补的cDNA探针进行了Northern印迹分析。我们已经证明,在TCDD处理(125微克/千克,口服)后4天和8天,与溶剂处理和配对喂养的对照动物相比,Sprague-Dawley大鼠肝脏中的PEPCK mRNA降低到非常低的水平。如Western印迹分析所示,PEPCK mRNA的这种下降与PEPCK蛋白水平的降低平行,并且伴随着PEPCK酶活性的降低。这些结果表明,TCDD导致的PEPCK活性降低很可能是PEPCK基因表达降低的结果。这些结果与之前的结果还表明,在经TCDD处理的动物中发生的许多生理反应(采食量减少、胰岛素降低、皮质酮增加、胰高血糖素和cAMP水平增加),这些通常会刺激PEPCK基因表达,但却无效。此外,色氨酸2,3-双加氧酶(TdO)活性,其调节方式与PEPCK活性非常相似,在TCDD处理后也降低,这表明TCDD改变这些酶调节的共同机制。在这些实验条件下,P-450 1A1 mRNA和相关的EROD活性被最大程度地诱导,并且代表了TCDD相关基因表达改变的阳性对照。然而,由于TCDD诱导的PEPCK活性降低和EROD活性诱导的剂量反应特征不同,不能假定Ah受体参与了PEPCK活性的降低。